Hemodynamic effects of parathyroid hormone-related peptide-(1-34) in humans.

It has been suggested that PTH-related peptide-(1-34) (PTHrP) is a regulator or modulator of regional or systemic cardiovascular function with varying vasodilating actions in different species. We have studied the cardiovascular pharmacodynamic profile of PTHrP in healthy humans. In a double blind, placebo-controlled, cross-over study design, eight healthy subjects were assigned to stepwise increased i.v. doses of PTHrP. In addition, a dose-response curve to PTHrP was constructed in a dorsal hand vein in eight subjects. PTHrP dose-dependently increased pulse rate and renal plasma flow by more than 50% (P < 0.0001 for both parameters, by ANOVA), but only a small venodilating response was seen in hand vein experiments, and no effect was noted on mean arterial blood pressure or cardiac inotropic performance. Although it is unlikely that PTHrP regulates systemic hemodynamics, its chronotropic effect and its potent action on renal plasma flow may represent the primary cardiovascular physiological targets of action.

[1]  M. Wolzt,et al.  Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: reversal by L-arginine. , 1997, The American journal of physiology.

[2]  A. F. Stewart,et al.  Parathyroid hormone-related protein detection and interaction with NO and cyclic AMP in the renovascular system. , 1996, Kidney international.

[3]  K. Endlich,et al.  Effect of intrarenally infused parathyroid hormone‐related protein on renal blood flow and glomerular filtration rate in the anaesthetized rat , 1996, British journal of pharmacology.

[4]  K. Kurokawa,et al.  Mechanical force regulation of vascular parathyroid hormone-related peptide expression. , 1996, Kidney international. Supplement.

[5]  D. Burkhoff,et al.  The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. , 1995, Endocrinology.

[6]  A. Fercher,et al.  Comparison of non-invasive methods for the assessment of haemodynamic drug effects in healthy male and female volunteers: sex differences in cardiovascular responsiveness. , 1995, British journal of clinical pharmacology.

[7]  K. Endlich,et al.  Vascular effects of parathyroid hormone and parathyroid hormone‐related protein in the split hydronephrotic rat kidney. , 1995, The Journal of physiology.

[8]  W. H. Aellig,et al.  Clinical pharmacology, physiology and pathophysiology of superficial veins--2. , 1994, British journal of clinical pharmacology.

[9]  W. H. Aellig,et al.  Clinical pharmacology, physiology and pathophysiology of superficial veins--1. , 1994, British journal of clinical pharmacology.

[10]  K. Kurokawa,et al.  Synergistic stimulation of parathyroid hormone-related peptide gene expression by mechanical stretch and angiotensin II in rat aortic smooth muscle cells. , 1994, The Journal of biological chemistry.

[11]  L. Deftos,et al.  Parathyroid hormone-related protein in the cardiovascular system. , 1994, Endocrinology.

[12]  T. Massfelder,et al.  Renin stimulating properties of parathyroid hormone-related peptide in the isolated perfused rat kidney. , 1993, Kidney international.

[13]  A. Malik,et al.  Parathyroid hormone related peptide gene expression in human fetal and adult heart. , 1993, Cardiovascular research.

[14]  J. Meyer,et al.  Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers , 1992, Clinical pharmacology and therapeutics.

[15]  G. Hendy,et al.  A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. , 1992, The Journal of clinical endocrinology and metabolism.

[16]  D. DiPette,et al.  Cardiovascular responsiveness to parathyroid hormone (PTH) and PTH-related protein in genetic hypertension. , 1992, Endocrinology.

[17]  T. Clemens,et al.  Abundant expression of parathyroid hormone-related protein in primary rat aortic smooth muscle cells accompanies serum-induced proliferation. , 1991, The Journal of clinical investigation.

[18]  A. Nana,et al.  Hypotension and cardiac stimulation due to the parathyroid hormone-related protein, humoral hypercalcemia of malignancy factor. , 1989, Endocrinology.

[19]  J. McEwan,et al.  Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison of their effects on resistance and capacitance vessels of human forearms. , 1988, Circulation.

[20]  W. Waugh,et al.  Simplified measurement of p-aminohippurate and other arylamines in plasma and urine. , 1974, Kidney international.

[21]  A. Weissler,et al.  Systolic Time Intervals in Heart Failure in Man , 1968, Circulation.

[22]  J. Orloff,et al.  Defining the roles of parathyroid hormone-related protein in normal physiology. , 1996, Physiological reviews.

[23]  A. F. Stewart,et al.  Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. , 1996, The Journal of clinical endocrinology and metabolism.

[24]  R. Marier,et al.  Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. , 1995, The Journal of clinical endocrinology and metabolism.

[25]  Jing Shan,et al.  Cardiovascular effects of human parathyroid hormone and parathyroid hormone-related peptide. , 1994, Journal of cardiovascular pharmacology.

[26]  L. Prescott,et al.  The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function. , 1993, British journal of clinical pharmacology.

[27]  D. DiPette,et al.  Regional and systemic hemodynamic effects of parathyroid hormone-related protein: preservation of cardiac function and coronary and renal flow with reduced blood pressure. , 1991, The Journal of pharmacology and experimental therapeutics.

[28]  T. Martin,et al.  Parathyroid hormone-related protein: isolation, molecular cloning, and mechanism of action. , 1989, Recent progress in hormone research.

[29]  E. Schnurr,et al.  Measurement of renal clearance of inulin and PAH in the steady state without urine collection. , 1980, Clinical nephrology.